Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Futreal

Showing results (31-40 of 388) with videos related to

Pageof 39
Sort By:
Plos Computational Biology|December 15, 2021
Statistical tests for intra-tumour clonal co-occurrence and exclusivityJack Kuipers, Ariane L Moore, Katharina Jahn, et al.
Iscience|February 4, 2021
Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroupsSanghoon Lee, Li Zhao, Latasha D Little, et al.
Human Genomics|December 14, 2004
Whole genome DNA copy number changes identified by high density oligonucleotide arraysJing Huang, Wen Wei, Jane Zhang, et al.
Genome Research|December 16, 2003
1-Mb resolution array-based comparative genomic hybridization using a BAC clone set optimized for cancer gene analysisJoel Greshock, Tara L Naylor, Adam Margolin, et al.
Cancer Research|January 28, 2010
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinomaDan Huang, Yan Ding, Ming Zhou, et al.
Plos One|June 17, 2020
Comparative genomics of high grade neuroendocrine carcinoma of the cervixR Tyler Hillman, Robert Cardnell, Junya Fujimoto, et al.
Blood Advances|January 23, 2023
TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasmHannah Beird, C Cameron Yin, Joseph D Khoury, et al.
Blood|October 6, 2005
The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disordersLinda M Scott, Peter J Campbell, E Joanna Baxter, et al.
Neuromuscular Disorders : NMD|July 8, 2008
Exclusion of biglycan mutations in a cohort of patients with neuromuscular disordersRachel A Peat, Jozef Gécz, Justin R Fallon, et al.
Genesis (New York, N.Y. : 2000)|July 26, 2011
Stella-Cre mice are highly efficient Cre deletersHui Liu, Wei Wang, Su-Kit Chew, et al.
Pageof 39

Showing results (31-40 of 388) with videos related to

Sort By:
Pageof 39
Plos Computational Biology|December 15, 2021
Statistical tests for intra-tumour clonal co-occurrence and exclusivityJack Kuipers, Ariane L Moore, Katharina Jahn, et al.
Iscience|February 4, 2021
Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroupsSanghoon Lee, Li Zhao, Latasha D Little, et al.
Human Genomics|December 14, 2004
Whole genome DNA copy number changes identified by high density oligonucleotide arraysJing Huang, Wen Wei, Jane Zhang, et al.
Genome Research|December 16, 2003
1-Mb resolution array-based comparative genomic hybridization using a BAC clone set optimized for cancer gene analysisJoel Greshock, Tara L Naylor, Adam Margolin, et al.
Cancer Research|January 28, 2010
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinomaDan Huang, Yan Ding, Ming Zhou, et al.
Plos One|June 17, 2020
Comparative genomics of high grade neuroendocrine carcinoma of the cervixR Tyler Hillman, Robert Cardnell, Junya Fujimoto, et al.
Blood Advances|January 23, 2023
TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasmHannah Beird, C Cameron Yin, Joseph D Khoury, et al.
Blood|October 6, 2005
The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disordersLinda M Scott, Peter J Campbell, E Joanna Baxter, et al.
Neuromuscular Disorders : NMD|July 8, 2008
Exclusion of biglycan mutations in a cohort of patients with neuromuscular disordersRachel A Peat, Jozef Gécz, Justin R Fallon, et al.
Genesis (New York, N.Y. : 2000)|July 26, 2011
Stella-Cre mice are highly efficient Cre deletersHui Liu, Wei Wang, Su-Kit Chew, et al.
Pageof 39